Akeso completes patient enrollment for Phase III Cadonilimab trial in high-risk HCC
Akeso, Inc. has announced the completion of patient enrollment for its Phase III cadonilimab trial (COMPASSION-22/AK104-306), marking a significant milestone in the clinical development of ... Read More
Akeso begins Phase 3 trial of cadonilimab as consolidation therapy for non-small cell lung cancer
Akeso, Inc. (9926.HK) has initiated its pivotal Phase 3 cadonilimab trial for non-small cell lung cancer (NSCLC), marking a significant advancement in immunotherapy research. The ... Read More
Akeso Biopharma raises $250m to accelerate international clinical trials
Akeso Biopharma has successfully raised approximately $250 million through a share placement, drawing significant recognition from international investment firms. The placement saw a majority of ... Read More